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Abstract
Background: Standard cardiovascular (CV) risk assessment may underestimate risk in
people with type 2 diabetes mellitus (T2DM). Cardiac and vascular imaging to detect
subclinical disease may augment risk prediction. This study investigated the association
between CV risk, left ventricular hypertrophy (LVH) and carotid intima-media thickness
(CIMT) in patients with T2DM free of CV symptoms.
Methods: People with T2DM without known CV disease were recruited from general
practice. The 5-year risk of CV events was calculated using an adjusted Framingham
equation and the prevalence of LVH and abnormal CIMT across bands of CV risk
assessed. In those at intermediate risk, the number needed to scan (NNS) to reclassify
one person to high risk was calculated across the group and compared in those above
and below 55 years. The association between LV mass and CIMT was also assessed.
Results: Mean age 57 years (SD11), 51% female. Median 5-year CV risk 14.3% (inter-
quartile range 10.3, 19.5), 51% had LVH (American Society of Echocardiography crite-
ria) and 31% an abnormal CIMT (age and sex criteria). In the 52% at intermediate risk,
37% had LVH and 36% an abnormal CIMT. The NNS was 1.7 using both imaging
techniques, 2.7 using cardiac imaging alone or 2.8 using vascular imaging alone. Almost
twice as many people >55 years had an abnormal CIMT than those <55 years.
Conclusions: Cardiac and vascular imaging to detect subclinical disease can be used to
augment prediction of CV risk in people with T2DM at intermediate risk. The value of re-
classifying risk is as yet unproven and requires outcome data from intervention studies.
Introduction
Cardiovascular disease (CVD) is the leading cause of mor-
tality and morbidity in people with type 2 diabetes mel-
litus (T2DM).1 Hypertension, dyslipidaemia and other CV
risk factors contribute to the increased CVD risk in
patients with T2DM. Standard CV risk assessment, incor-
porating conventional risk factors such as age, blood
pressure (BP), smoking status and cholesterol, may
underestimate risk. CV risk is a continuum and improv-
ing risk estimation, especially in those assessed as having
intermediate risk, may help to identify those patients
with T2DM that would benefit most from more intensive
CV management.
Left ventricular hypertrophy (LVH) and carotid intima-
media thickness (CIMT) are markers of subclinical CVD
and may reflect the accumulated effect of exposure to risk
factors which are unrecognized or underrepresented by
classic risk equations. LVH is associated with CVmorbidity
andmortality, independent of established risk factors such
as age, sex and diabetes.2,3 There is a positive, linear
relationship between LV mass and CV events in the
general population4 and among patients with essential
hypertension.5 Diabetes is associated with LVH6 and a
large proportion of patients with T2DM without known
CVD have LVH7. CIMT is a marker of atherosclerotic
burden and has previously been associated with LV
mass.8–10 The relationship between CIMT and the
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development of CVD has led to it being recommended as
an adjunct to risk prediction particularly in those esti-
mated to be at low to intermediate CVD risk.11–14 Previous
studies suggest that 20–30% of people considered at low
or intermediate risk by Framingham risk assessment
equations are reclassified to high risk on the basis of
abnormal CIMT.15,16 However, the role of CV imaging for
reclassification of risk in patients with T2DM without
known CVD has not been tested, and thus remains
uncertain.
The aim of this study was to assess the association
between CV risk, LVH and CIMT in patients with T2DM
without known CVD.
Methods
Study population
The second Natriuretic Peptides in the Community study
was a prospective cross-sectional study in New Zealand
that sought to compare the value of NT-proBNP with
electrocardiography (ECG) in the detection of LVH
among patients in primary care with T2DM and no
known CVD. The methods and results have been
described previously.17 The study was approved by the
local ethics committee, and informed consent was
obtained from all subjects. Briefly, ethnically diverse par-
ticipants with T2DM for >5 years and/or on treatment for
T2DM, but without known CV, cerebrovascular or
peripheral arterial disease were recruited from general
practice in 2006–2007. CV risk factors were prevalent:
60% had hypertension, 70% had dyslipidaemia and 56%
met American Society of Echocardiography (ASE) sex-
specific criteria for LVH. The study found that while
NT-proBNP was superior to ECG for the detection of LVH,
it was unsuitable as a screening tool for LVH in patients
with T2DM. The present study includes 298 patients in
whom LV mass, CIMT and CV risk could be assessed.
Estimation of cardiovascular risk
The 5-year absolute risk of CVD events was estimated
on the basis of age, sex, smoking, diabetes, BP and
total : high-denisty lipoprotein (HDL) cholesterol using a
Framingham equation.18 Variable definitions differed
from those in the equation in that smoking was defined
as being a current smoker only and did not include
smoking in the past year, and ECG-defined LVH was not
included as it is not routinely used for risk assessment in
clinical practice.
To improve calibration of the Framingham equation in
the New Zealand population, the New Zealand Guide-
lines Group (NZGG) recommends that 5% be added to
the absolute risk estimate for one of: a family history of
premature ischaemic CVD or ischaemic stroke in a first-
degree relative, being of a high-risk ethnicity (Maori,
Pacific, Indian subcontinent), or having advanced
diabetes (of more than 10 years duration or HbA1c con-
sistently greater than 8% or the presence of microalbu-
minuria).19 A single adjustment is made for people with
more than one of the above criteria. In those with a risk
estimate of less than 15%, but with extreme values of
cholesterol (total or total : HDL  8) or BP (170 mmHg
systolic or 100 mmHg diastolic), the NZGG recommend
they be classified as being at 15% risk. The adjustment for
ethnicity has subsequently been validated in a review of
over 27 000 patients.20 Low risk is defined as a 5-year
absolute risk of a CVD event of less than 5%, inter-
mediate risk is 5–15% and high risk is 15%.
Left ventricular hypertrophy
All patients underwent a transthoracic echocardiogram
(Philips iE33, Bothell, WA, USA). LV mass was calcu-
lated from m-mode images in accordance with the ASE
recommendations21 and indexed to body surface area.
LVH was defined by both the ASE (women > 95 g/m2,
men > 115 g/m2)21 and the European Society of Hyper-
tension (ESH) (women > 110 g/m2, men > 125 g/m2)22
guidelines.
Carotid intima-media thickness
Carotid artery imaging was performed using a Sonosite
Micromaxx (Bothell, WA, USA). The CIMT of the far wall
of the right distal common carotid artery was manually
measured from B-mode images in accordance with ASE
recommendations.23 The reference range used to define
abnormality was selected to match the method of
measurement used in the study. Therefore, an abnormal
CIMT was defined as above the 75th centile of age- and
sex-specific ranges developed in the Atherosclerosis Risk
in the Community (ARIC) study.24,25
Approach to analysis
The prevalence of LVH and abnormal CIMT across
increasing bands of risk were presented visually as bar-
plots, with the trend in proportions assessed using linear
regression. In those at intermediate risk, the number
needed to scan (NNS) to reclassify one person was calcu-
lated as the number at risk divided by the number that
would be reclassified by one or both of the imaging tech-
niques. The degree of overlap in risk reclassification by
the presence of LVH or an abnormal CIMT is presented
visually using Venn diagrams. These assessments were
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made in the whole cohort, and after dividing into groups
above and below 55 years of age.
The relationship between CIMT and LV mass was
assessed using scatterplots and Pearson’s linear correla-
tion coefficient. To assess the practical relevance of the
association between CIMT and LV mass, 95% prediction
intervals were calculated on the basis of univariable and
multiple linear regressions of LV mass on CIMT. In the full
model, mass was adjusted for age (years), sex, height
(cm), systolic BP (mmHg) and hypertensive treatment
(Y/N).
All analyses were performed using R statistical
software.26
Results
Variables required for calculation of risk, LV mass and
CIMT were available in 298 subjects and their character-
istics are summarized in Table 1. The mean age was
57 years (SD 11) and half were female. Median duration
of diabetes was 6 years (interquartile range (IQR) 3.3, 10)
and median HbA1c was 7.1% (IQR 6.4, 8.3). Microalbu-
minuria was present in 25% (n = 74) and macroalbumin-
uria in 11% (n = 31).
Whole group
Risk
The majority of the study subjects (87%, n = 260) had 5%
added to their Framingham risk estimate as recommended
by the New Zealand Guidelines. Over two-thirds of these
(68%, n = 178)moved up one risk band solely on the basis
of their ethnicity, irrespective of the levels of any other
factors. Themedian 5-year risk of a CVD event was 14.3%
(IQR 10.3, 19.5). As expected, themean value of each risk
factor increased as risk increased, with those at more than
20% risk being predominantly male, older (mean age
64 years), hypertensive (mean BP 147/84 mmHg) and
with elevated total : HDL cholesterol (mean 4.0).
Only four people were at <5% risk. All were white,
normotensive, non-smokers, with no family history of
premature ischaemic CVD. Three were men aged
<50 years, all had total : HDL cholesterol <3.5 and
albumin creatinine ratio <0.5.
Left ventricular hypertrophy and carotid
intima-media thickness
The prevalence of LVH was 51% by ASE criteria and 35%
by ESH criteria. As shown in Figure 1a and 1b, the pro-
portion of LVH by either criterion increased with increas-
ing risk (average of 16% per risk band with ASE criteria;
13% per risk band with European Society of Cardiology
(ESC) criteria) and the linear trend was significant (P 
0.0001 for both).
The prevalence of an abnormal CIMT was 31% by age-
and sex-specific criteria. The median CIMT increased as
risk increased (Table 1); however, the proportion of those
classified as having an abnormal CIMT by age- and sex-
specific criteria decreased with increasing risk (Fig. 1c).
Table 1 Group characteristics
5-year risk of CVD (%)
All <5 5–10 10–15 15–20 >20
n (%) 298 4 (1) 61 (20) 93 (31) 68 (23) 72 (24)
Diabetes
Diabetes duration, years 6.0 (3.3, 11.0) 5.5 (3.8, 7.8) 5.0 (2.0, 8.0) 5.2 (3.0,8.3) 6.0 (3.0 12.0) 10.0 (6.0, 14.5)
HbA1c, % 7.1 (6.4, 8.3) 6.4 (6.0, 6.9) 6.8 (6.1, 8.1) 7.1 (6.5, 8.1) 7.1 (6.5, 8.9) 7.5 (6.6, 8.7)
Risk factors
Female, n (%) 151 (51) 1 (25) 35 (57) 42 (45) 41 (60) 32 (44)
Age, yearrs 57 (11) 50 (7) 48 (9) 57 (8) 59 (10) 64 (10)
SBP, mmHg 135 (18) 120 (12) 121 (12) 130 (9) 143 (17) 147 (20)
DBP, mmHg 82 (11) 78 (10) 78 (10) 80 (8) 85 (1) 84 (12)
Total : HDL 3.6 (1.0) 2.9 (0.6) 3.2 (0.9) 3.5 (1.1) 3.7 (1.0) 4.0 (1.0)
Smoking, n (%) 47 (16) 0 8 (13) 7 (8) 13 (19) 19 (26)
Imaging
LV mass, g 211 (166, 258) 250 (219, 252) 176 (141, 212) 195 (161, 243) 228 (179, 266) 246 (210, 287)
LVH by ASE, n (%) 153 (51) 2 (50) 14 (23) 43 (46) 39 (57) 55 (76)
LVH by ESH, n (%) 105 (35) 2 (50) 8 (13) 26 (28) 29 (43) 40 (56)
CIMT, mm 0.75 (0.65, 0.86) 0.60 (0.58, 0.62) 0.69 (0.62, 0.76) 0.74 (0.6, 0.87) 0.75 (0.66, 0.86) 0.81 (0.73, 0.92)
Abnormal CIMT, n (%) 92 (31) 0 27 (44) 29 (31) 20 (29) 16 (22)
Values are presented as mean (standard deviation) or median (interquartile range) unless otherwise stated.
ASE, American Society of Echocardiography; CIMT, carotid intima-media thickness; CVD, cardiovascular disease; DBP, diastolic blood pressure; ESH,
European Society of Hypertension; HDL, high-denisty lipoprotein; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.
CV imaging risk assessment of diabetics
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Intermediate risk
Fifty-two per cent of the group (n = 154) were at inter-
mediate risk (5–15%). Of these, 50% were female, mean
age 53 years, mean BP 126/79 mmHg, total : HDL cho-
lesterol was 3.4 and 10% were current smokers. LVH was
present in 37% by ASE criteria or 22% by ESH criteria,
and 36% had an abnormal CIMT.
The distributions of LVH and CIMT in this group are
summarized in Figure 2. When LVH is defined using ASE
criteria, 22% had LVH only and so would be reclassified
to high risk on this basis, 21% would be reclassified on
the basis of an abnormal CIMT only and 15% had both
conditions. Using both echocardiography and carotid
imaging, the NNS to reclassify one person is 1.7. If only
one imaging technique is used, the NNS is 2.7 for echo
and 2.8 for carotid imaging (however, more than 20% of
people would not be reclassified using a single imaging
technique).
When LVH is defined using ESC criteria, 12% would be
reclassified to high risk on the basis of LVH only, 26% on
the basis of an abnormal CIMT only and 10% had both
conditions. Using both imaging modalities, the NNS is
2.1, with echo only is 4.5 and with carotid imaging only
is 2.8. Imaging with a single technique will not reclassify
26% and 12% respectively.
Effect of age
Age influences both CIMT and estimates of risk; there-
fore, the correlation between CIMT and risk is attenuated
after adjustment for age, particularly in the higher risk
bands. Figure 3 shows the effect of dividing the group at
a nominal threshold of 55 years. In those aged less than
55 years, the prevalence of abnormal CIMT in people at
intermediate (5–15%) risk is almost twice that of those
aged over 55 years (46% vs 24%).
LV mass is not correlated to age and so is not adjusted
for age when categorized to LVH. In those at intermediate
risk, there is a greater difference in the proportion of LVH
above and below 55 years using ASE than ESC criteria
(Fig. 3).
Figure 2 Proportion reclassified by one or both imaging modalities, in
those at mild to moderate risk. Abn CIMT, abnormal carotid intima-media
thickness; LVH (ASE), left ventricular hypertrophy as defined by American
Society of Echocardiography criteria; LVH (ESH), left ventricular hypertro-
phy as defined by European Society of Hypertension criteria.
Figure 1 LVH and CIMT per band of 5-year cardiovascular risk. ASE, American Society of Echocardiography; CIMT, carotid intima-media thickness; ESH,
European Society of Hypertension; light bar, within normal limits; LVH, left ventricular hypertrophy.
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Left ventricular mass and carotid
intima-media thickness
The relationship between LV mass and CIMT is shown in
Figure 4. The linear correlation coefficient (r) is 0.22
(95% CI 0.11, 0.33). The correlation is significantly dif-
ferent from zero (P = 0.0001); however, the 95% predic-
tion intervals for LV mass are extremely wide over the
range of CIMT values, with little difference after adjusting
CIMT for age, sex, height, systolic BP and hypertensive
treatment (Fig. 4b). A CIMT of 0.63 mmwill predict mass
as being from 72 to 338 g (univariate) or 92 to 322 g
(multivariate). Similarly, a CIMT of 0.98 mm will predict
mass of 101 to 368 g (univariate) or 117 to 347 g (mul-
tivariate).
Discussion
In this study of a community cohort of people with T2DM
and without symptomatic CVD, over half were at inter-
mediate risk of a CV event in the next 5 years based on
standard risk factors. Despite these patients having
Figure 3 LVH and CIMT per band of 5-year cardiovascular risk, divided by age. ASE, American Society of Echocardiography; CIMT, carotid intima-media
thickness; ESH, European Society of Hypertension; light bar, within normal limits; LVH, left ventricular hypertrophy.
Figure 4 Scatterplots of CIMT and LV mass showing confidence and prediction intervals from (a) univariate and (b) multivariate analyses. CIMT, carotid
intima-media thickness; dashed line, 95% prediction interval; dotted line, 95% confidence interval; LV, left ventricular; solid line, correlation.
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T2DM, there is uncertainty in CV and diabetes guidelines
about how to manage CV risk.1,12,27 Consequently,
improvement in risk prediction, especially among those
in the intermediate-risk group, may provide more cer-
tainty on which to base appropriate management inter-
ventions. The results from the current study demonstrate
that a combined imaging strategy, with cardiac and vas-
cular imaging, may reclassify risk among those within the
intermediate-risk group.
As both CIMT and LVH are markers of subclinical
disease and are associated with CV events, it is relevant to
consider the use of imaging techniques to augment risk
prediction, especially in those at intermediate risk.11,12,23
Disease can occur in any part of the vascular system and
so manifests as different events. Differing event rates and
individual propensity to stroke, myocardial infarction
(MI), or peripheral arterial disease are consistent with
different mechanisms underlying the spectrum of CVD,
and it would be unreasonable to expect one technique to
identify all events for reclassification. Recent data support
this concept; for example, the Multi-Ethnic Study of Ath-
erosclerosis found that coronary artery calcium (CAC)
score was more predictive of CHD and CVD compared
with CIMT, which was more predictive of stroke,28 and
recent genetic studies have identified a locus on chromo-
some 9p that is associated with MI and CAD, and with
CAC score, but not with CIMT.29
Distribution of subclinical disease across
risk categories
In the current study, the prevalence of LVH within each
risk band increased with increasing risk. Importantly, LVH
was present at all levels of risk, and at least 20% of the
group at intermediate risk would be reclassified to high
risk on this basis. Conversely, using age- and sex-specific
thresholds, the prevalence of an abnormal CIMT did not
increase with increasing risk and may even decrease. Yet,
unadjusted CIMT has been shown in this study and oth-
ers30,31 to increase with increasing risk. This relationship
appears to be driven by the confounding effect of age:
when the effect of age is removed (by categorizing to
age-specific ranges), the relationship between CIMT and
risk is attenuated. This is in contrast to LV mass, which is
not affected by age, and in which the positive relationship
with risk persists after categorization.
The effect of age is confirmed when stratifying the
current data into two age bands, that is, above and below
55 years. The low prevalence of abnormal CIMT per risk
band in those over 55 years shows that few people in this
group would have risk status changed on the basis of an
abnormal CIMT; however, LVH is prevalent and could be
used. At least half of those <55 years have an abnormal
CIMT, across all risk groups, suggesting that CIMT may
improve risk stratification in younger people. One poten-
tial limitation though is that the reference values for
CIMT are mainly derived from patients aged >45 years,24
and thus the utility of CIMT in patients <45 years is
uncertain.
Intermediate risk
Abnormal CIMT and LVH are found in a similar propor-
tion of patients in the intermediate-risk group, although
these are not the same individuals. Less than a quarter of
those with either an abnormal CIMT or LVH have both
abnormalities. The lack of overlap of the two conditions
may represent different aspects of the risk profile of
T2DM, or may represent different stages of disease
development.
Reclassification of risk
The combined high prevalence of LVH and an abnormal
CIMT in those at intermediate risk meant that the NNS to
reclassify risk was very low (NNS = 1.7). Although
21–22% of people will not be reclassified if only one
imaging technique is used (using ASE criteria), the NNS is
still 2.8 with CIMT, and 2.7 with echocardiography.
Incorporation of cardiac and/or carotid imaging in risk
assessment requires consideration of the extra time and
cost of these procedures, as well as the availability of
technology and suitably qualified personnel.12 A targeted
approach of measuring LV mass and CIMT in a diabetic
clinic, for example, would minimize these costs.
Although relatively low, the inter- and intra-individual
variability of image acquisition and measurement are
important considerations for use in individual patients.
Automated border detection for measurement of CIMT is
recommended to limit variability in measurement,23
although this is not consistently used.24
Correlation between left ventricular
hypertrophy and carotid
intima-media thickness
CIMT is associated with LV mass although the linear
correlation (r) between them is weak, especially in
non-hypertensive subjects. Consistent with previous
studies,8–10 we found the correlation coefficient to be sig-
nificantly different from zero (P = 0.0001); however, the
low value of the coefficient (r = 0.22) and wide prediction
intervals show that it is not a clinically significant rela-
tionship. The lack of association between CIMT and LV
mass, however, supports the principle that the two
approaches assess different aspects of subclinical disease,
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and that use of both may improve the estimation of CV
risk.
Limitations
Adjustments to the risk estimate that are currently recom-
mended inNewZealandGuidelines had a significant effect
on the distribution of risk in this study. Eighty-seven per
cent of the cohort had their risk estimate adjusted
upwards, two-thirds of which was due to being of a high-
risk ethnicity regardless of any other reason for adjust-
ment. Subsequent studies have shown that although the
ethnicity adjustment is suitable, adjusting for family
history is not.20 This may be due to a confounding effect
between family history and ethnicity, which may also
confound with the adjustments for advanced diabetes;
however, these have not been addressed. Consequently,
we cannot confirm the validity of non-ethnic adjustments.
The reference range used to define an abnormal CIMT
impacts on the prevalence of disease. The thresholds used
in this study were those developed from the ARIC cohort
(imaged in 1987–1989).24 Older imaging systemswill gen-
erally have poorer resolution than current systems, thus
CIMT values measured now may be lower than those
imaged on an oldermachine. Subsequently, the amount of
abnormal CIMT in current imagesmay be underestimated
by using reference ranges formulated using older technol-
ogy.23 This study included people of ethnicities at increased
CV risk; therefore, thresholds of abnormal CIMT estab-
lished in theARIC cohortmay not be optimal. However, in
the absence of a local reference range being available, a
range recommended by the ASE was used.
Of the range of imaging measurements that are avail-
able, LVH and CIMT were selected as they have a proven
association with CV risk. The accuracy and reproducibil-
ity of echocardiographic LV mass may be less than that of
cardiac magnetic resonance imaging (MRI); however,
MRI is not widely available and would cost more than
echocardiography in a population such as this.
Conclusion
Accurate risk stratification for patients with T2DM is
important to assist with decisions regarding preventative
interventions; yet, standard risk assessment is suboptimal
in this group. Cardiac and vascular imaging, to detect
subclinical disease, can be used to augment risk predic-
tion. The value of such imaging is likely to be greatest
among those at intermediate risk in whom management
may be less clear. Detection of abnormal CIMT and the
presence of LVH would reclassify up to 58% of patients at
intermediate risk to high risk, but the value of reclassify-
ing risk is as yet unproven, and there remains a need for
outcome data from appropriately designed intervention
studies demonstrating that treatment interventions will
improve outcome.
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